国产创新药安罗替尼抗肿瘤治疗的研究进展

血管新生是恶性肿瘤细胞增殖、生长、转移过程中的重要环节,抗肿瘤血管新生药物在肿瘤治疗中起重要作用。安罗替尼是我国自主研发的多靶点小分子酪氨酸激酶抑制剂,其主要作用于血管内皮生长因子受体(VEGFR)-1、VEGFR-2、VEGFR-3、血小板衍生生长因子受体、成纤维细胞生长因子受体、c-Kit、Ret等多个靶点,可以阻断肿瘤血管生成并抑制肿瘤生长。多项临床试验证实安罗替尼在非小细胞肺癌、软组织肉瘤、小细胞肺癌、甲状腺髓样癌、肾癌和结直肠癌中均具有良好的疗效和安全性。

Research progress on antitumor therapy of domestic innovative medicine anlotinib

Angiogenesis is an important link in the process of proliferation,growth and metastasis of malignant tumor cells.Anti-tumor angiogenesis drugs play an important role in tumor therapy.Alotinib is a multi-targeted small molecule tyrosine kinase inhibitor which independently researched and developed in China.It mainly targets vascular endothelial growth factor receptor(VEGFR)-1,VEGFR-2,VEGFR-3,platelet-derived growth factor receptor,fibroblasts growth factor receptor,c-Kit,Ret to block tumor angiogenesis and inhibit tumor growth.Several clinical trials have demonstrated that alotinib has good efficacy and safety in the treatment of non-small cell lung cancer,soft tissue sarcoma,small cell lung cancer,medullary thyroid carcinoma,renal carcinoma and colorectal cancer.